BR0105563A - Derivados e análogos de galantamina - Google Patents

Derivados e análogos de galantamina

Info

Publication number
BR0105563A
BR0105563A BR0105563-1A BR0105563A BR0105563A BR 0105563 A BR0105563 A BR 0105563A BR 0105563 A BR0105563 A BR 0105563A BR 0105563 A BR0105563 A BR 0105563A
Authority
BR
Brazil
Prior art keywords
analogs
galantamine derivatives
galantamine
derivatives
general formula
Prior art date
Application number
BR0105563-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ulrich Jordis
Johannes Froehlich
Matthias Treu
Manfred Hirnschall
Laszlo Czollner
Beate Kaelz
Stefan Welzig
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of BR0105563A publication Critical patent/BR0105563A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0105563-1A 2000-03-31 2001-03-22 Derivados e análogos de galantamina BR0105563A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
AT2382001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (de) 2000-03-31 2001-03-22 Neue derivate und analoga von galanthamin

Publications (1)

Publication Number Publication Date
BR0105563A true BR0105563A (pt) 2002-04-02

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0105563-1A BR0105563A (pt) 2000-03-31 2001-03-22 Derivados e análogos de galantamina

Country Status (26)

Country Link
US (2) US7166588B2 (OSRAM)
EP (1) EP1181294B1 (OSRAM)
JP (1) JP2003529602A (OSRAM)
CN (1) CN1380883A (OSRAM)
AT (1) ATE263171T1 (OSRAM)
AU (1) AU785385B2 (OSRAM)
BG (1) BG65134B1 (OSRAM)
BR (1) BR0105563A (OSRAM)
CA (1) CA2368966A1 (OSRAM)
CZ (1) CZ300160B6 (OSRAM)
DE (1) DE50101827D1 (OSRAM)
DK (1) DK1181294T3 (OSRAM)
ES (1) ES2215885T3 (OSRAM)
HK (1) HK1049832A1 (OSRAM)
HU (1) HUP0202233A3 (OSRAM)
IS (1) IS2287B (OSRAM)
MX (1) MXPA01012275A (OSRAM)
NO (1) NO326458B1 (OSRAM)
NZ (1) NZ516302A (OSRAM)
PL (1) PL202463B1 (OSRAM)
PT (1) PT1181294E (OSRAM)
RU (1) RU2241001C2 (OSRAM)
SI (1) SI1181294T1 (OSRAM)
SK (1) SK285909B6 (OSRAM)
TR (1) TR200400857T4 (OSRAM)
WO (1) WO2001074820A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
CN1646536A (zh) * 2002-03-25 2005-07-27 萨诺化学萨物股份公司 制备降雪花胺以及其异构体、盐和水合物的方法
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
CN102007129B (zh) 2008-04-14 2014-05-07 神经动力生命科学公司 用作治疗人类脑疾病的前药的雪花胺衍生物
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
EP2583168B1 (en) 2010-06-15 2017-11-08 Ab Initio Technology LLC Dynamically loading graph-based computations
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
CA2932763C (en) 2013-12-05 2022-07-12 Ab Initio Technology Llc Managing interfaces for dataflow graphs composed of sub-graphs
EP3189418B1 (en) 2014-09-02 2022-02-23 AB Initio Technology LLC Visually specifying subsets of components in graph-based programs through user interactions
CN107077364B (zh) 2014-09-02 2021-06-04 起元科技有限公司 基于特定数据端口连接的识别使用图组件的自动聚类的基于图的程序规范的编译
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968B (zh) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922B (zh) * 2024-11-22 2025-12-09 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
NZ294191A (en) * 1994-10-21 1998-10-28 Waldheim Pharmazeutika Gmbh Process for preparing 4a,5,9,10,11,12-hexahydro-6h-benzofuro[3a,3,2-ef][2]benzazepine derivatives and intermediates thereof
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
WO2000032199A1 (de) * 1998-12-01 2000-06-08 Sanochemia Pharmazeutika Aktiengesellschaft Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
MXPA01012275A (es) 2003-06-24
WO2001074820A1 (de) 2001-10-11
NO326458B1 (no) 2008-12-08
NO20015857L (no) 2002-01-29
ATE263171T1 (de) 2004-04-15
HK1045990A1 (en) 2002-12-20
AU4208501A (en) 2001-10-15
SI1181294T1 (en) 2004-08-31
CN1380883A (zh) 2002-11-20
DE50101827D1 (de) 2004-05-06
JP2003529602A (ja) 2003-10-07
DK1181294T3 (da) 2004-08-02
US7166588B2 (en) 2007-01-23
CZ20014178A3 (cs) 2002-11-13
HUP0202233A2 (hu) 2002-11-28
NO20015857D0 (no) 2001-11-30
BG106155A (en) 2002-08-30
EP1181294B1 (de) 2004-03-31
NZ516302A (en) 2004-02-27
PL352638A1 (en) 2003-09-08
SK17022001A3 (sk) 2003-02-04
RU2241001C2 (ru) 2004-11-27
TR200400857T4 (tr) 2004-06-21
AU785385B2 (en) 2007-03-29
US20030199493A1 (en) 2003-10-23
ES2215885T3 (es) 2004-10-16
CZ300160B6 (cs) 2009-02-25
HK1049832A1 (zh) 2003-05-30
PL202463B1 (pl) 2009-06-30
SK285909B6 (sk) 2007-10-04
CA2368966A1 (en) 2001-10-11
PT1181294E (pt) 2004-07-30
IS6174A (is) 2001-11-23
EP1181294A1 (de) 2002-02-27
US20070027138A1 (en) 2007-02-01
BG65134B1 (bg) 2007-03-30
HUP0202233A3 (en) 2004-12-28
IS2287B (is) 2007-10-15

Similar Documents

Publication Publication Date Title
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
SE0000540D0 (sv) New compounds
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NL300877I2 (nl) obeticholzuur
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
PT1181294E (pt) Novos derivados e analogos da galantamina
CY1107634T1 (el) Φαρμακευτικη συνθεση
CY1116145T1 (el) S-φθορομεθυλεστερας 6.αλφα.,9.αλφα-διφθορο-17.αλφα.-'(2-φουρανυλκαρβοξυλ) οξυ]-11.βητα.-υδροξυ-16.αλφα.-μεθυλ-3-οξο-ανδροστ-1,4-διεν-17-καρβοθειοτικου οξεος ως αντιφλεγμονωδης παραγοντας
BR9902086A (pt) Formulações farmacêuticas.
CY1116988T1 (el) Βητα-l-2'-δεοξυ-νουκλεοζιτες για την θεραπεια ηπατιτιδας β
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
DE60121461D1 (de) Kondensierte pyridoindolderivate
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
BR9804027A (pt) Novos beta-ceto ésteres
SE9901077D0 (sv) Novel use
DE60120427D1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
SE9801494D0 (sv) Novel use
AU4609701A (en) Colouring agent for keratin containing fibres
DE60112960D1 (de) Kondensierte pyridoindolderivate
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
DE69819539D1 (de) Antithrombotische mittel
BRPI0416678A (pt) pirazolpirimidinas
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.